Despite decades of progress in pharmaceutical R&D, the earliest phase of drug discovery—where molecules are conceived and designed—remains costly, inefficient, and burdened by high failure rates. Most ...

In their Research review article, “Generative Artificial Intelligence in Medical Imaging: Foundations, Progress, and Clinical ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Typeface is continuing to advance its customized generative AI agenda ...

Antibodies are popularly used in therapeutics due to their drug-like properties, such as minimal immunogenic effects and increased target selectivity. The first step for the development of an antibody ...

The FDA's decision on a chatbot for patients recovering from surgery could offer clues on how the agency plans to regulate ...

Generative AI (GenAI) is dominating headlines, and for good reason. For many, it may have felt like the technology came out of nowhere and rocketed into every domain, from art to education to business ...

John R. Lumpkin ([email protected]), Blue Cross and Blue Shield of North Carolina Foundation, Durham, North Carolina. Merry Davis, Blue Cross and Blue Shield of North Carolina Foundation. Valerie ...

Explore how differing strategies and risk profiles set these two tech ETFs apart for investors seeking sector exposure.

Get the latest federal technology news delivered to your inbox. The normally secretive Central Intelligence Agency isn’t shying away from its use of generative artificial intelligence tools across ...

I’ve since rewatched the conference once more while rewinding specific moments many times over to analyze them. I’ve also given myself a couple of days to re-assess whether my rose-tinted Google ...